Most antibiotics are designed to kill bacteria without harming your cells, and they accomplish this by targeting structures that bacterial cells have but your cells don’t. However, the separation isn’t perfect. Several classes of antibiotics do interact with eukaryotic cells, sometimes causing side effects and sometimes producing surprisingly useful results.
Why Most Antibiotics Spare Your Cells
Antibiotics work through a principle called selective toxicity: they exploit the structural and biochemical differences between bacterial (prokaryotic) cells and the eukaryotic cells that make up your body. Bacteria have unique features, like a rigid cell wall made of peptidoglycan, a different type of ribosome for building proteins, and certain metabolic pathways that human cells simply lack. Antibiotics zero in on these differences.
The most straightforward example is penicillin and other beta-lactam antibiotics. These drugs block the construction of peptidoglycan, the mesh-like scaffold that surrounds every bacterial cell and keeps it from bursting. Your cells have no peptidoglycan whatsoever. There’s nothing for the drug to act on, so it passes through your body without disrupting your own tissues. Another clean example is sulfonamides, which interfere with how bacteria manufacture folic acid (a B vitamin). Your cells don’t make folic acid at all; you get it from food. So the drug hits a pathway that only exists in bacteria.
The Ribosome Difference
Many common antibiotics, including tetracyclines, macrolides, and aminoglycosides, kill bacteria by jamming their protein-building machinery: the ribosome. Bacterial ribosomes are smaller (classified as 70S) than the ribosomes in your cells (80S), and they differ enough in shape that these drugs bind tightly to the bacterial version while largely ignoring the human one.
Tigecycline, a powerful tetracycline-class drug, illustrates this well. It locks onto a specific site on the bacterial ribosome and physically blocks the cell from reading its genetic instructions. At normal doses in the body, tigecycline does not bind to human cytoplasmic (80S) ribosomes at all. Only at artificially high concentrations in the lab does it start to latch onto human ribosomes at a secondary binding site, producing a mild inhibitory effect on protein production. Under real clinical conditions, the selectivity holds.
Where the Line Gets Blurry: Mitochondria
Here’s where the story gets more complicated. Your cells contain mitochondria, the organelles that generate energy. Mitochondria descended from ancient bacteria that were absorbed by early eukaryotic cells billions of years ago, and they still retain their own ribosomes. Those mitochondrial ribosomes (55S in humans) resemble bacterial ribosomes far more closely than they resemble the 80S ribosomes in the rest of your cell.
This means antibiotics that target bacterial protein synthesis can also interfere with mitochondrial protein synthesis. Tetracyclines are potent inhibitors of mitochondrial translation, with measurable effects on rat heart and liver cells at low concentrations. Doxycycline, one of the most commonly prescribed tetracyclines, disrupts the balance between proteins made by mitochondria and proteins made by the cell’s nucleus, even at doses as low as 0.5 micrograms per milliliter. This imbalance has been demonstrated in multiple human cell lines.
Tetracyclines aren’t alone. Chloramphenicol shuts down mitochondrial translation by binding to the same ribosomal site it targets in bacteria. Macrolides like azithromycin and erythromycin bind inside the exit tunnel of both bacterial and mitochondrial ribosomes, disrupting protein assembly. Oxazolidinones (like linezolid) damage mitochondrial function badly enough that patients can develop lactic acidosis, nerve damage, and metabolic problems. Aminoglycosides, amphenicols, lincosamides, and streptogramins all block mitochondrial protein production, often without affecting the cytoplasmic ribosome at all.
Aminoglycosides and Hearing Loss
Aminoglycoside antibiotics like gentamicin work by binding to a specific spot on bacterial ribosomal RNA, causing the cell to misread its genetic code and produce defective proteins. In human mitochondrial ribosomes, that same binding site has a small chemical difference (an A-to-G substitution) that normally prevents aminoglycosides from latching on effectively. This is what protects most people.
But some people carry inherited mitochondrial DNA mutations, most notably m.1555A>G and m.1494C>T, that reshape their mitochondrial ribosome to look more like a bacterial one. In these individuals, aminoglycosides bind to the mitochondrial ribosome with much higher affinity, reducing protein synthesis by roughly 30% on top of already impaired function. The energy-producing capacity of affected cells drops, and toxic byproducts called reactive oxygen species build up. Because aminoglycosides tend to accumulate in the inner ear, this process can trigger irreversible hearing loss. The drug selectively concentrates in the delicate hair cells of the cochlea, and when mitochondrial protein production falls below a critical threshold, those cells die.
Tetracyclines and Bone
Tetracyclines have another interaction with eukaryotic tissue that has nothing to do with ribosomes. These molecules naturally grab onto metal ions, especially calcium. Since bone and developing teeth are rich in hydroxyapatite (a calcium-containing mineral), tetracyclines bind directly to the bone matrix. In children, this causes permanent yellow-brown staining of teeth and can affect bone growth. This calcium-chelating property is so reliable that researchers actually use fluorescent tetracycline labels to study bone formation rates.
Some Antibiotics Affect DNA in Human Cells
Fluoroquinolones like ciprofloxacin kill bacteria by targeting an enzyme called DNA gyrase, which bacteria need to unwind and copy their DNA. Human cells don’t have DNA gyrase, but they do have a related enzyme, topoisomerase II, that performs similar functions. Certain fluoroquinolones, particularly those with a fluorine atom at both the C-6 and C-8 positions of their chemical structure, are potent inhibitors of this human enzyme. They increase the levels of broken DNA intermediates and impair the enzyme’s ability to relax supercoiled DNA. Removing the C-8 fluorine reduces this effect roughly 2.5-fold, which is why drug designers have worked to minimize this cross-reactivity. Still, the overlap between bacterial and human enzyme targets helps explain why fluoroquinolones can cause tendon damage, nerve problems, and other side effects that go beyond simple infection treatment.
Antibiotics That Modulate Your Immune System
Macrolide antibiotics like azithromycin and erythromycin do something unexpected in human cells: they dial down inflammation. This isn’t an accident of toxicity. These drugs actively influence signaling pathways inside your immune cells. Erythromycin blocks the release of key inflammatory signals from human bronchial cells. Clarithromycin reduces the production of inflammatory markers in human epithelial cell lines. Multiple 14-membered macrolides suppress the activation of NF-kB, a master switch for inflammation, in both airway cells and immune cells in the blood.
Azithromycin pushes immune cells called macrophages toward an anti-inflammatory state, characterized by higher production of calming signals like IL-10 and lower output of inflammatory ones like IL-12. It also reduces IL-17 production by a specific subset of T-cells in a dose-dependent manner. Two studies have shown macrolides directly suppress a growth-signaling pathway called mTOR in T-cells, dampening their proliferative response. These immunomodulatory effects are why macrolides are sometimes prescribed long-term for chronic inflammatory lung diseases like diffuse panbronchiolitis and certain cases of COPD, where their value comes from calming the immune response rather than killing bacteria.
Why Antibacterials Don’t Work on Fungi
Fungi are eukaryotes, just like your cells, which is precisely why standard antibacterial antibiotics are useless against fungal infections. A fungal cell has 80S ribosomes, no peptidoglycan cell wall, and the same basic metabolic toolkit as your own cells. The targets that antibacterials exploit in bacteria simply aren’t there.
Antifungal drugs need their own version of selective toxicity. They exploit the fact that fungal cell membranes contain ergosterol instead of the cholesterol found in human membranes. Triazole antifungals block ergosterol production. Polyene antifungals bind directly to ergosterol and punch holes in the fungal membrane. Echinocandins target the synthesis of beta-glucans in the fungal cell wall, a structure human cells lack entirely. These are narrow differences, which is why antifungal drugs tend to have more side effects than antibacterials: the gap between “toxic to the fungus” and “toxic to you” is much smaller when both cells are eukaryotic.